Literature DB >> 18460981

Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases.

Guangming Han1, C Blake Gilks, Samuel Leung, Carol A Ewanowich, Julie A Irving, Teri A Longacre, Robert A Soslow.   

Abstract

There are conflicting data about chemoresistance and prognosis in ovarian clear cell carcinoma (CCC). This could be due to significant interobserver variation in the diagnosis of CCC and other ovarian surface epithelial tumors containing clear cells. Thirty-two cases previously diagnosed as CCC, high-grade ovarian serous carcinoma (SC), and mixed surface epithelial carcinoma (SEC) with clear cell and serous components were reviewed by 4 gynecologic pathologists blinded to the original diagnoses. Interobserver reproducibility was evaluated. Each case was also assessed using immunohistochemical markers Wilm tumor 1, estrogen receptor, and p53. The interobserver reproducibility was greatest for pure CCC (kappa of 0.82), and lowest for the mixed SEC (kappa of 0.32). Moderate agreement was seen in the pure SC category (kappa of 0.59). All pure SC and most mixed SEC presented as stage III or IV diseases. Most pure CCC presented as stage I or II diseases. Immunoreactivities of the mixed SECs were similar to those of pure SC, but significantly different from those of pure CCC for Wilm tumor 1 (P=0.0011 for both components), estrogen receptor (P=0.0003 for clear cell component, P=0.0001 for serous component), and p53 (P=0.0062 for both components). The serous and clear cell components of mixed SEC showed higher mitotic rates than pure CCC (P=0.004 and P=0.023, respectively), but the mitotic rate of pure SC was similar to the mixed SEC. We conclude that (1) pure CCC is reproducibly diagnosed. (2) The diagnosis of mixed ovarian SEC with clear cell component is not reproducible. (3) Mixed SEC with clear cell and serous components show similar stage, mitotic activities, and immunoreactivities to those of pure SC, and likely represent SC with clear cell changes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18460981     DOI: 10.1097/PAS.0b013e318164edf7

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  8 in total

1.  Clinicopathological heterogeneity in ovarian clear cell adenocarcinoma: a study on individual therapy practice.

Authors:  Yuji Matsuo; Hironori Tashiro; Hiroyuki Yanai; Takuya Moriya; Hidetaka Katabuchi
Journal:  Med Mol Morphol       Date:  2014-11-15       Impact factor: 2.309

2.  HNF-1β in ovarian carcinomas with serous and clear cell change.

Authors:  Deborah DeLair; Guangming Han; Julie A Irving; Samuel Leung; Carol A Ewanowich; Teri A Longacre; Cyril B Gilks; Robert A Soslow
Journal:  Int J Gynecol Pathol       Date:  2013-11       Impact factor: 2.762

3.  BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

Authors:  Kathryn Alsop; Sian Fereday; Cliff Meldrum; Anna deFazio; Catherine Emmanuel; Joshy George; Alexander Dobrovic; Michael J Birrer; Penelope M Webb; Colin Stewart; Michael Friedlander; Stephen Fox; David Bowtell; Gillian Mitchell
Journal:  J Clin Oncol       Date:  2012-06-18       Impact factor: 44.544

4.  Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers.

Authors:  Robertson Mackenzie; Aline Talhouk; Sima Eshragh; Sherman Lau; Daphne Cheung; Christine Chow; Nhu Le; Linda S Cook; Nafisa Wilkinson; Jacqueline McDermott; Naveena Singh; Friedrich Kommoss; Jacobus Pfisterer; David G Huntsman; Martin Köbel; Stefan Kommoss; C Blake Gilks; Michael S Anglesio
Journal:  Am J Surg Pathol       Date:  2015-11       Impact factor: 6.394

5.  Clear cell histology as a poor prognostic factor for advanced epithelial ovarian cancer: a single institutional case series through central pathologic review.

Authors:  Morikazu Miyamoto; Masashi Takano; Tomoko Goto; Masafumi Kato; Naoki Sasaki; Hitoshi Tsuda; Kenichi Furuya
Journal:  J Gynecol Oncol       Date:  2013-01-08       Impact factor: 4.401

6.  Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials.

Authors:  Michael L Friedlander; Kenneth Russell; Sherri Millis; Zoran Gatalica; Ryan Bender; Andreas Voss
Journal:  Int J Gynecol Cancer       Date:  2016-05       Impact factor: 3.437

7.  Clear cell carcinomas of the ovary: a mono-institutional study of 73 cases in China with an analysis of the prognostic significance of clinicopathological parameters and IMP3 expression.

Authors:  Rui Bi; Xuxia Shen; Weiwei Zhang; Yufan Cheng; Zheng Feng; Xu Cai; Wentao Yang
Journal:  Diagn Pathol       Date:  2016-02-02       Impact factor: 2.644

8.  Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA.

Authors:  Madalene A Earp; Linda E Kelemen; Anthony M Magliocco; Kenneth D Swenerton; Georgia Chenevix-Trench; Yi Lu; Alexander Hein; Arif B Ekici; Matthias W Beckmann; Peter A Fasching; Diether Lambrechts; Evelyn Despierre; Ignace Vergote; Sandrina Lambrechts; Jennifer A Doherty; Mary Anne Rossing; Jenny Chang-Claude; Anja Rudolph; Grace Friel; Kirsten B Moysich; Kunle Odunsi; Lara Sucheston-Campbell; Galina Lurie; Marc T Goodman; Michael E Carney; Pamela J Thompson; Ingo B Runnebaum; Matthias Dürst; Peter Hillemanns; Thilo Dörk; Natalia Antonenkova; Natalia Bogdanova; Arto Leminen; Heli Nevanlinna; Liisa M Pelttari; Ralf Butzow; Clareann H Bunker; Francesmary Modugno; Robert P Edwards; Roberta B Ness; Andreas du Bois; Florian Heitz; Ira Schwaab; Philipp Harter; Beth Y Karlan; Christine Walsh; Jenny Lester; Allan Jensen; Susanne K Kjær; Claus K Høgdall; Estrid Høgdall; Lene Lundvall; Thomas A Sellers; Brooke L Fridley; Ellen L Goode; Julie M Cunningham; Robert A Vierkant; Graham G Giles; Laura Baglietto; Gianluca Severi; Melissa C Southey; Dong Liang; Xifeng Wu; Karen Lu; Michelle A T Hildebrandt; Douglas A Levine; Maria Bisogna; Joellen M Schildkraut; Edwin S Iversen; Rachel Palmieri Weber; Andrew Berchuck; Daniel W Cramer; Kathryn L Terry; Elizabeth M Poole; Shelley S Tworoger; Elisa V Bandera; Urmila Chandran; Irene Orlow; Sara H Olson; Elisabeth Wik; Helga B Salvesen; Line Bjorge; Mari K Halle; Anne M van Altena; Katja K H Aben; Lambertus A Kiemeney; Leon F A G Massuger; Tanja Pejovic; Yukie T Bean; Cezary Cybulski; Jacek Gronwald; Jan Lubinski; Nicolas Wentzensen; Louise A Brinton; Jolanta Lissowska; Montserrat Garcia-Closas; Ed Dicks; Joe Dennis; Douglas F Easton; Honglin Song; Jonathan P Tyrer; Paul D P Pharoah; Diana Eccles; Ian G Campbell; Alice S Whittemore; Valerie McGuire; Weiva Sieh; Joseph H Rothstein; James M Flanagan; James Paul; Robert Brown; Catherine M Phelan; Harvey A Risch; John R McLaughlin; Steven A Narod; Argyrios Ziogas; Hoda Anton-Culver; Aleksandra Gentry-Maharaj; Usha Menon; Simon A Gayther; Susan J Ramus; Anna H Wu; Celeste L Pearce; Malcolm C Pike; Agnieszka Dansonka-Mieszkowska; Iwona K Rzepecka; Lukasz M Szafron; Jolanta Kupryjanczyk; Linda S Cook; Nhu D Le; Angela Brooks-Wilson
Journal:  Hum Genet       Date:  2013-11-05       Impact factor: 4.132

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.